Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. liver failure
Show results for
Products
Services
Applications

Companies

News
Articles

Refine by
Date

  • Older

Liver Failure Articles & Analysis: Older

15 news found

Alexandra Clyde appointed to Sequana Medical Board of Directors

Alexandra Clyde appointed to Sequana Medical Board of Directors

Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, today announces the appointment of Alexandra Clyde as an independent Non-Executive Director of the Company. ...

BySequana Medical NV


Sequana Medical secures EUR 10 million loan facility with Kreos Capital

Sequana Medical secures EUR 10 million loan facility with Kreos Capital

Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of drug-resistant fluid overload in liver disease and heart failure, today announces it has entered into a secured loan facility agreement of EUR 10 million with Kreos Capital VI (UK) Limited (“Kreos”). ...

BySequana Medical NV


Sequana Medical completes enrollment in Phase 2a SAHARA I DSR study, reports disease-modifying profile for Short Term DSR and provides business update

Sequana Medical completes enrollment in Phase 2a SAHARA I DSR study, reports disease-modifying profile for Short Term DSR and provides business update

DSR (Direct Sodium Removal) heart failure drug development: Completed enrollment in SAHARA I[i] with first-generation DSR product (“DSR 1.0”) – extending study with second-generation DSR product (“DSR 2.0”) to support US IND[ii] filing by year end Proof-of-concept delivered in diuretic-resistant heart failure patients with ...

BySequana Medical NV


Doug Kohrs appointed to Sequana Medical Board of Directors

Doug Kohrs appointed to Sequana Medical Board of Directors

Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of drug-resistant fluid overload in liver disease and heart failure, today announces the appointment of Doug Kohrs as an independent Non-Executive Director of the Company. ...

BySequana Medical NV


Lumos Pharma Announces a Clinical Collaboration with Massachusetts General Hospital (MGH) to Evaluate Oral LUM-201 in Nonalcoholic Fatty Liver Disease (NAFLD) in a Phase 2 Investigator-Initiated Trial

Lumos Pharma Announces a Clinical Collaboration with Massachusetts General Hospital (MGH) to Evaluate Oral LUM-201 in Nonalcoholic Fatty Liver Disease (NAFLD) in a Phase 2 Investigator-Initiated Trial

Hepatic steatosis can progress to nonalcoholic steatohepatitis (NASH) with fibrosis, and NASH-associated liver failure is one of the leading causes of liver transplant in the United States. ...

ByLumos Pharma


Bristol Myers Squibb (NYSE: BMY) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen

Bristol Myers Squibb (NYSE: BMY) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen

Bristol-Myers Squibb K.K. today announced that Japan’s Ministry of Health, Labour and Welfare has approved Abecma (idecabtagene vicleucel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy, for the treatment of adult patients with relapsed or refractory (R/R) multiple myeloma, who have received at least three prior therapies, including an ...

ByBristol Myers Squibb Corporate


HemoShear Identifies Second Target to Treat Nash for Takeda

HemoShear Identifies Second Target to Treat Nash for Takeda

In addition, Nature Scientific Reports published the company’s research analyzing gene expression at various stages of nonalcoholic fatty liver disease. NASH, one of the leading causes of transplantation, is a serious, chronic liver disease that is estimated to impact over 16 million people in the United States alone. NASH is characterized by inflammation ...

ByHemoShear Therapeutics, Inc.


Dicerna Presents Data From Phase 1 Trial of Belcesiran at American Association for the Study of Liver Diseases (AASLD) The Liver MeetingĀ® 2021

Dicerna Presents Data From Phase 1 Trial of Belcesiran at American Association for the Study of Liver Diseases (AASLD) The Liver MeetingĀ® 2021

The data were presented in a poster at The Liver Meeting® 2021, the annual meeting of the American Association for the Study of Liver Diseases (AASLD). “In people with AATLD, misfolded AAT aggregates in the liver and causes liver injury that may progress to liver fibrosis, cirrhosis and hepatocellular ...

ByNovo Nordisk A/S


A Complete Overview of a Life Saving Treatment - Liver Transplantation in India

A Complete Overview of a Life Saving Treatment - Liver Transplantation in India

Hepatic transplant or liver transplant is a treatment that includes the replacement of diseased liver with the healthy liver from another individual. It is a surgical treatment to remove the non-functional liver (liver failure) and replace it with the healthy liver (from a ...

ByLiver Transplant India


Why do you require to have a Liver transplant?

Why do you require to have a Liver transplant?

If anyhow, your liver stops working properly, you may need a liver transplant. Liver Transplant India is generally recommended if you have a last-stage liver disease, which is chronic liver failure. This is a life-threatening and serious liver disease, and this is be caused by ...

ByLiver Transplant India


Berlin Heart Today Announces CE Approval and First Implantation of an Innovative Bridging Solution for Single Ventricle Patients

Berlin Heart Today Announces CE Approval and First Implantation of an Innovative Bridging Solution for Single Ventricle Patients

Nevertheless, for many patients, the time comes, when due to worsening heart failure the only remaining hope is a donor heart. With the aim of giving these patients a chance to bridge the sometimes very long waiting times, Berlin Heart has developed the EXCOR® Venous Cannula. ...

ByBerlin Heart GmbH


Thermo Fisher Scientific and Daiichi Sankyo to Co-Develop Global Companion Diagnostic for Patients with Non-Small Cell Lung Cancer

Thermo Fisher Scientific and Daiichi Sankyo to Co-Develop Global Companion Diagnostic for Patients with Non-Small Cell Lung Cancer

Thermo Fisher Scientific and Daiichi Sankyo have expanded their partnership by signing a new agreement to co-develop a companion diagnostic (CDx) that will utilize Thermo Fisher's next-generation sequencing (NGS)-based Oncomine Dx Target Test. The CDx will be designed to identify non-small cell lung cancer (NSCLC) patients with human epidermal growth factor receptor 2 (HER2) mutations who may be ...

ByThermo Fisher Scientific, LIMS & Laboratory Software


154 died of heat stroke in New York City from 2000-11: said CDC

154 died of heat stroke in New York City from 2000-11: said CDC

John Gicking, a board-certified specialist in critical care with BluePearl in Tampa, Fla., previously explained to CBSNews.com that pets should be given plenty of water and shade where they can escape the heat. “They can develop organ failure including kidney, lung and liver failure, bleeding problems where they can’t clot blood and ...

ByScarlet Tech Ltd.


Newly Discovered Cells Restore Liver Damage in Mice without Cancer Risk

The liver is unique among organs in its ability to regenerate after being damaged. ...

ByNational Institute of Environmental Health Sciences (NIEHS)


Merck to initiate proof-of-concept study of posaconazole for chronic chagas disease, recognized by WHO as one of the world`s neglected tropical diseases

Merck to initiate proof-of-concept study of posaconazole for chronic chagas disease, recognized by WHO as one of the world`s neglected tropical diseases

Rarely, more severe hepatic reactions including cholestasis or hepatic failure including fatalities were reported in patients with serious underlying medical conditions (e.g., hematologic malignancies) during treatment with posaconazole. Liver function tests should be monitored at the start of and during the course of therapy. Discontinuation of NOXAFIL must be ...

ByCSRwire - Corporate Social Responsibility Newswire

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT